We have previously reported an association between the same AhRArg554Lys polymorphism and ER status in breast cancer, and that this polymorphism impacted response to endocrine switch-therapy with sequential tamoxifen/AI or AI/tamoxifen (12). This evidence concerns the gene ESR1 and breast carcinoma.